Nasal Powder for Acute Migraine Gets FDA Nod

FDA resurrects Satsuma's nasal migraine treatment

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency

Nasal Powder for Acute Migraine Gets FDA Nod

(MedPage Today) -- The FDA approved dihydroergotamine (DHE) nasal powder (Atzumi) 5.2 mg to treat acute migraine with or without aura in adults, Satsuma Pharmaceuticals announced Wednesday. The product is the only DHE nasal powder for acute migraine...

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

Atzumi™ (dihydroergotamine(DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults in an easy-to-use, easy-to-carry device.Atzumi is the first and only product utilizing the SMART (Simple MucoAdhesive…

FDA Approves Satsuma’s STS101 Nasal Powder For Acute Migraine - Data Intelligence

Image Credit: © yodiyim – stock.adobe.com The FDA has approved Satsuma’s STS101 dihydroergotamine (DHE) nasal powder under the name of Atzumi as a new treatment for adults with acute migraine, with or without aura. The approval is based on positive results from the Phase III ASCEND clinical trial as well as a Phase I pharmacokinetic study.1 In a press release, Ryoichi Nagata, MD, PhD, FFPM, president and CEO of Satsuma, said: “The approval of At…

FDA Approves Atzumi, Nasal Powder Formulation of DHE, for Acute Treatment of Migraine

In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.

FDA approves Satsuma's migraine nasal spray after rejection in 2024

The FDA approved a new nasal spray for migraines that was developed by Satsuma Pharmaceuticals. Previously called STS101, the company said Wednesday that the drug's brand name is Atzumi and is ...